Access 53 recently approved and available drugs and 22 investigational drugs on the short list for approval.
Last week we added 12 new drugs to the knowledgebase:
The FDA approved abrocitinib (Cibinqo, Pfizer), on 1/14/2022, for the treatment of adults with refractory, moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with other systemic therapies. Like other JAK inhibitors, abrocitinib was approved with a boxed warning regarding the increased risk for serious infections, mortality, malignancy, major cardiovascular events and thrombosis. Announced Research Updates Sarepta announced data from 20 patients enrolled in Part 2 of a 48-week, 41 patient, Phase II trial, where treatment with delandistrogene moxeparvovec improved the NSAA score by two points compared to a 103 patient, weighted external control group (1.3 point increase vs 0.7 point decrease). We also added six new published research updates that subscribers can review
Comments are closed.
|
Stay informed, subscribe to the
Prescribe Right Pharmaceutical Pipeline Tracker Latest Tweets from Prescribe Right
Archives
June 2023
|
Services |
Company |
Support |
© COPYRIGHT 2015. ALL RIGHTS RESERVED.
|